Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Chris Tran, Samedy Ouk, Nicola J. Clegg, Yu Chen, Philip A. Watson, Vivek Arora, John Wongvipat, Peter M. Smith-Jones, Dongwon Yoo, Andrew Kwon, Teresa Wasielewska, Derek Welsbie, Charlie Degui Chen, Celestia S. Higano, Tomasz M. Beer, David T. Hung, Howard I. Scher, Michael E. Jung, Charles L. Sawyers

    Research output: Contribution to journalArticle

    1362 Scopus citations

    Abstract

    Metastatic prostate cancer is treated with drugs that antagonize androgen action, but most patients progress to a more aggressive form of the disease called castration-resistant prostate cancer, driven by elevated expression of the androgen receptor. Here we characterize the diarylthiohydantoins RD162 and MDV3100, two compounds optimized from a screen for nonsteroidal antiandrogens that retain activity in the setting of increased androgen receptor expression. Both compounds bind to the androgen receptor with greater relative affinity than the clinically used antiandrogen bicalutamide, reduce the efficiency of its nuclear translocation, and impair both DNA binding to androgen response elements and recruitment of coactivators. RD162 and MDV3100 are orally available and induce tumor regression in mouse models of castration-resistant human prostate cancer. Of the first 30 patients treated with MDV3100 in a Phase I/II clinical trial, 13 of 30 (43%) showed sustained declines (by >50%) in serum concentrations of prostate-specific antigen, a biomarker of prostate cancer. These compounds thus appear to be promising candidates for treatment of advanced prostate cancer.

    Original languageEnglish (US)
    Pages (from-to)787-790
    Number of pages4
    JournalScience
    Volume324
    Issue number5928
    DOIs
    StatePublished - May 8 2009

    ASJC Scopus subject areas

    • General

    Fingerprint Dive into the research topics of 'Development of a second-generation antiandrogen for treatment of advanced prostate cancer'. Together they form a unique fingerprint.

  • Cite this

    Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., Wasielewska, T., Welsbie, D., Chen, C. D., Higano, C. S., Beer, T. M., Hung, D. T., Scher, H. I., Jung, M. E., & Sawyers, C. L. (2009). Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science, 324(5928), 787-790. https://doi.org/10.1126/science.1168175